You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Rapid automated polarizable multipole-based force field parameterization for accurate drug-receptor binding affinity calculations.

    SBC: DRUG DESIGN METHODOLOGIES, L.L.C.            Topic: 500

    PROJECT SUMMARY ABSTRACTDrug Design MethodologiesChris HoM DPh DThis SBIR will develop automated software to accurately estimate drug target binding affinity and selectivityThis capability is crucial to drug discoveryyet remains elusive in all current design toolsOur technology identifies favorable candidates and distinguishes problematic ones that could exhibit side effects due to weak or non sel ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Glycoengineering a bioconjugate vaccine against Klebsiella pneumoniae

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an increasingly prevalent drug resistant nosocomial pathogenCommonlyKpneumoniae isolates are carbapenem resistantwhich are referred to as carbapenem resistant EnterobacteriaceaeCREand present significantly less therapeutic intervention optionsFurthermorecommunity acquired infections associated with hypervirulent isolates of Kpneumoniae have emerged that are ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Inhibitor of the Classical Pathway of Complement

    SBC: AnthroBio, Inc.            Topic: NHLBI

    A novel inhibitor of the classical pathway of the complement system Abstract The classical pathway of the complement system is implicated in the pathogenesis of a number of human autoimmune diseasesincluding systemic lupus erythematosusrheumatoid arthritisalloantibody mediated transplant rejection and autoimmune hemolytic anemiaDespite a large body of literature documenting the role of the complem ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Minimizing bloodstream infection detection time using laser light-scattering

    SBC: BacterioScan            Topic: NIAID

    PROJECT SUMMARY Bloodstream infectionsBSIsrepresent a very serious clinical manifestation that can be caused by a variety of bacterial and fungal pathogensmany of which have been associated with high rates of mortalityPhysicians caring for patients with BSIs are challenged with having very limited time to make an effective diagnosisincluding identification of the causative agent and determination ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Using Augmented Reality To Make Cardiac Ablation Procedures Simpler and Safer

    SBC: SENTIAR, INC.            Topic: NHLBI

    Abstract The goal of this SBIR FastTrack application is to deliver an augmented realityARplatform technology that displays an interactiveD cardiac hologram to make ablation procedures simpler and saferWorld widecardiac ablations are used as therapy formillion arrhythmia patients every yearThere ishoweversignificant skill required to perform these procedures and only a handful of cases can be perfo ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting

    SBC: NUVOX PHARMA, L.L.C.            Topic: 101

    PROJECT SUMMARY ABSTRACT Clinical ChallengeIn acute traumain the civilian settinghemorrhage is the second most leading cause of deathIn the military settingof potentially preventable deaths are caused by hemorrhage due to traumaof civilian andof military mortality caused by traumatic hemorrhage occurs pre hospitalizationAdverse outcome in trauma patients during prehospital resuscitation is due to ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS

    SBC: RESTORE THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARYAcute Respiratory Distress SyndromeARDSis a devastating syndrome that afflicts more thanpatients in United States alone and has an unacceptably high mortality rate ofCurrently there are no therapies that address the loss of lung vascular barrier integrityvascular leakage and alveolar flooding that are critical features of ARDS pathobiologyThe PI was the first to demonstrate that sph ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThe Aurora Kinase FamilyAKFcomprises heavily pursued therapeutic targets for cancer because of their intimate involvement in cell division and tumor progressionNumerous therapeutic campaigns have been initiated against the AKFwith promising clinical successes emanating from strategies targeting either Aurora A or Aurora BHoweverthe US Food and Drug Administration has yet to approve a cance ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Synergistic Anti-tumor Efficacy of an Interleukin 2 Analog and PD-1 blockade

    SBC: APT THERAPEUTICS, INC.            Topic: 102

    Principal Investigator Program DirectorLastFirstMiddleChenRidong Abstract The durable clinical efficacy of immune checkpoint inhibitors in a variety of cancers has demonstrated the tremendous potential of tumor immunotherapyHowevercurrent approaches are limited to immunogenic tumors that acquire adaptive resistanceInterleukinILimmunotherapy can result in remarkable long term responses in some canc ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Immunomodulatory Therapy for Neuropathic Pain

    SBC: APT THERAPEUTICS, INC.            Topic: 101

    Principal Investigator Program DirectorLastFirstMiddleRidong Chen Project SummaryNeuropathic pain can be difficult to treat with onlyof patients achieving meaningfulandgtpain reliefCurrent therapiese ggabapentinmainly address symptoms by focusing on blocking neurotransmission in the pain pathway with limited efficacypotentially severe side effects and narrow therapeutic indexThusnovel therapies ar ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government